中国肌肉减少症诊疗指南(2024版)  

Guideline for diagnosis and treatment of sarcopenia in China(2024 edition)

作　　者：中华医学会老年医学分会 国家老年疾病临床医学研究中心(湘雅医院) 雷光华[2] 于普林[3] 唐佩福[4] 翁习生[5] 王伊伦 曾超[2] 魏捷 吴紫莺 The Geriatrics Branch of the Chinese Medical Association;The National Clinical Research Center for Geriatric Disorders(Xiangya Hospital);Lei Guanghua;Yu Pulin(不详;Department of Orthopedics,Xiangya Hospital,Central South University,the National Clinical Research Center for Geriatric Disorders(Xiangya Hospital),Changsha 410008,China;the National Clinical Research Center for Geriatrics,Beijing Hospital,Beijing 100730,China)

机构地区：[1]不详 [2]中南大学湘雅医院骨科,国家老年疾病临床医学研究中心(湘雅医院),长沙410008 [3]北京医院国家老年医学中心,北京100730 [4]解放军总医院骨科医学部 [5]中国医学科学院北京协和医院骨科

出　　处：《中华医学杂志》2025年第3期181-203,共23页National Medical Journal of China

基　　金：国家重点研发计划(2022YFC3601900、2022YFC2505500);国家老年疾病临床医学研究中心(湘雅医院)临床研究基金(2022LNJJ07)。

摘　　要：肌肉减少症(简称“肌少症”)是一种与增龄相关、以肌肉含量减少、肌肉力量下降和(或)躯体功能障碍为主要特征的老年综合征,可增加衰弱、跌倒、残疾甚至死亡等不良结局的发生风险,疾病负担沉重。规范肌少症的诊断及治疗对开展临床工作和促进我国健康老龄事业发展具有重要意义,但目前我国尚缺乏基于循证医学证据的肌少症临床诊疗指南。基于此,由国家老年疾病临床医学研究中心(湘雅医院)牵头,在中华医学会老年医学分会组织下,遵循《中国制订/修订临床诊疗指南的指导原则(2022版)》和国际实践指南报告规范(RIGHT)等指南制订指导文件,遴选出肌少症领域最为关注的12个重要临床问题。采用推荐意见分级的评价、制定及评估(GRADE)体系评估证据强度,并运用德尔菲共识法确定推荐强度,最终形成18条关于肌少症诊疗的循证医学推荐意见。本指南旨在提高我国肌少症诊疗的科学性,并推动我国肌少症科研工作的深入发展,以期最终提升以患者为中心的医疗服务质量。Sarcopenia,an aging-related geriatric syndrome,is characterized by decreased muscle mass,declined muscle strength,and/or physical dysfunction.It is associated with significantly increased risks of falls,frailty,disability,and even death,placing a heavy burden on individuals and society.Standardized diagnosis and treatment of sarcopenia are of paramount importance for clinical practice and the development of healthy aging in China.However,to date,there is a lack of evidence-based clinical practice guideline for the diagnosis and treatment therapy of sarcopenia in China.Therefore,the National Clinical Research Center for Geriatric Diseases(Xiangya Hospital)has initiated the development of this guideline for sarcopenia,with the approval of Geriatrics Branch of the Chinese Medical Association.Development of this guideline adhered to the Guiding principles for development/revision of clinical practice guidelines in China(2022 version)and the Reporting Items for Practice Guidelines in Healthcare(RIGHT).The Grading of Recommendations Assessment,Development and Evaluation(GRADE)system was used to assess the strength of evidence.The Delphi technique was used to determine the strength of recommendations.Finally,a total of 18 evidence-based recommendations for the diagnosis and treatment of sarcopenia were formulated in response to 12 most concerned important clinical questions about sarcopenia.This guideline aims to enhance the scientific approach to sarcopenia diagnosis and treatment in China,promote the in-depth development of sarcopenia research,and ultimately improve the quality of patient-centered healthcare services.

关 键 词：肌肉减少症 诊断 治疗 临床实践指南 循证医学 

分 类 号：R685[医药卫生—骨科学]